+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Octreotide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 140 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294528
The octreotide market size was valued at USD 2.71 billion in 2026 and is estimated to grow from USD 3.01 billion in 2027 to reach USD 5.01 billion by 2032, at a CAGR of 10.78% during the forecast period (2027-2032). This report is Segmented by Product Type (Branded, Generic), Formulation (Immediate-Release, LAR Suspension, Depot Microsphere, and More), Route (Subcutaneous, and More), Indication (Acromegaly, Gastroenteropancreatic Neuroendocrine Tumors, and More, End User (Hospitals, Specialty and Endocrinology Clinics, Oncology Centers, and More), and Geography (North America, Europe, and More). Forecasts in Value (USD).

Global Octreotide Market Trends and Insights

Expanding Use in Neuroendocrine Tumors: Octreotide as the Backbone of Combination Regimens

Gastroenteropancreatic neuroendocrine tumor incidence in the United States reached 6.1 cases per 100,000 people, while the 20-year limited-duration prevalence totaled 248,546 cases as of January 1, 2021. This expanding patient base supports recurring demand in the octreotide market, as treatment often continues over extended periods. The PROMID study reported median progression-free survival of 14.3 months with octreotide long-acting release (LAR), compared with 6.0 months with placebo, supporting its antiproliferative use in appropriate patients. The European Society for Medical Oncology continues to recognize somatostatin analog therapy in its guidance for neuroendocrine and endocrine tumors. Octreotide also supports radioligand therapy regimens, with NETTER-2 reporting progression-free survival of 23.0 months for lutetium-177 dotatate plus octreotide, compared with 8.5 months for octreotide alone. Wider radioligand therapy availability at specialist centers may further support demand among patients with higher disease burden. Coordinated oncology and endocrinology care, including imaging, biochemical assessment, and treatment reviews, reinforces demand for established therapies and continuity of treatment.

Persistent Demand for Acromegaly Maintenance Therapy: Injectable SSAs Retain the Hardest-to-Treat Cohort

Acromegaly requires long-term biochemical monitoring and continued treatment for many patients. Debiopharm reported that up to 77% of patients receiving standard monthly somatostatin analog regimens experienced injection-site adverse events. However, the need to maintain biochemical control makes treatment interruption difficult despite the burden of regular injections. This supports demand for established injectable therapies among responsive patients and creates opportunities for formulations that reduce administration frequency. Paltusotine received Food and Drug Administration (FDA) approval in September 2025 as a once-daily oral, non-peptide somatostatin receptor subtype 2 agonist for adults with acromegaly. Injectable somatostatin analogs remain relevant for patients requiring established maintenance approaches, particularly those with incomplete insulin-like growth factor 1 control who may need treatment escalation. Improved diagnosis in emerging health systems can expand the treated patient pool and support the projected 12.45% growth rate for acromegaly within the octreotide market.

Generic Price Erosion in Long-Acting-Release Products: Revenue Compression Beneath Volume Expansion

Novartis reported USD 1.21 billion in 2025 sales for the Sandostatin LAR (long-acting release) group, reflecting a 5% decline at constant currency. Generic entry in the United States remains a key driver of lower realized prices for branded long-acting-release products. This pressure can continue even as patient treatment volumes increase, as payers favor lower-cost alternatives that meet coverage requirements. Consequently, branded revenue can decline despite stable or expanding treatment volumes. Although Sandostatin LAR benefits from established prescribing patterns and specialist familiarity, price differentials can affect hospital purchasing and payer coverage decisions. Manufacturers must strengthen their value proposition through competitive contracting, supply reliability, and clinical administration support.

Other drivers and restraints analyzed in the detailed report include:

  1. Generic Long-Acting-Release Entry Expanding Treatment Access: The Access-Erosion Paradox
  2. Oral and Self-Administered Somatostatin-Pathway Innovation: Formulation Pipeline More Active Than at Any Prior Period
  3. Buy-and-Bill and Site-of-Care Reimbursement Friction: A Structural Barrier to Clinic-Level Adoption

Segment Analysis

Generic octreotide is projected to grow at a compound annual growth rate (CAGR) of 12.67% through 2032. Teva’s October 2024 United States launch introduced a generic long-acting release (LAR) option in a category historically led by the originator brand. Generic products can expand treatment access where pricing influences prescribing decisions and coverage. They can also prompt purchasing groups and health plans to reassess preferred-product designations.

Branded octreotide held a 53.45% share of the octreotide market in 2026. Branded products retain advantages through clinical familiarity, established distribution arrangements, and existing treatment protocols. Novartis reported Sandostatin LAR group sales of USD 1.21 billion in 2025, confirming the franchise’s continued commercial scale. Generic competition will continue to pressure brand pricing and formulary placement, while suppliers compete on access, pricing, and supply reliability.

Long-acting-release injectable suspension captured 58.56% of formulation revenue in 2026. The format supports regular maintenance treatment for neuroendocrine tumors and acromegaly. Monthly dosing provides clinicians with a familiar approach to monitoring disease control and managing treatment schedules. Established hospital workflows and trained providers continue to support its market position.

Depot microsphere injection is projected to grow at a 11.68% CAGR from 2027 to 2032. The technology requires precise control of polymer properties, drug loading, and release behavior, which can limit new competitor entry. Immediate-release injections continue to address acute-care needs, including esophageal variceal bleeding. Oral candidates, such as T25, represent a separate development pathway, subject to further clinical and regulatory progress.

Complete Report Scope:

  • By Product Type
    • Branded Octreotide
    • Generic Octreotide
  • By Formulation
    • Immediate-Release Injection
    • Long-Acting-Release Injectable Suspension
    • Depot Microsphere Injection
    • Other Extended-Release Formulations
  • By Route of Administration
    • Subcutaneous
    • Intravenous
    • Intramuscular
    • Oral and Other Investigational Routes
  • By Indication
    • Acromegaly
    • Gastroenteropancreatic Neuroendocrine Tumors
    • Carcinoid Syndrome
    • Vasoactive Intestinal Peptide-Secreting Tumors
    • Secretory Diarrhea
    • Esophageal Variceal Bleeding
    • Other Clinical Indications
  • By End User
    • Hospitals
    • Specialty Clinics
    • Endocrinology Clinics
    • Oncology Centers
    • Ambulatory Care Centers
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America is projected to account for a 39.88% share of the octreotide market in 2026. The region benefits from established specialty care infrastructure, broad access to endocrinology and oncology providers, and the long-standing Sandostatin franchise. Teva’s 2024 launch of a generic long-acting release option in the United States is expected to influence purchasing decisions among payers and providers managing high-cost specialty medicines. Hospitals and specialist practices will continue to influence the pace of product switching, while new self-administered approaches may expand the range of care settings over time.

Asia-Pacific is forecast to grow at a compound annual growth rate (CAGR) of 13.77% during 2027-2032. Expanding specialty care capacity and broader treatment access across major health systems will support this growth. Triastek is expected to receive U.S. Food and Drug Administration (FDA) investigational new drug clearance for T25 in April 2026, introducing an oral development pathway that supports the region’s innovation base. Funding levels and diagnostic capacities vary across Asia-Pacific countries; therefore, adoption is unlikely to be uniform. However, improved access to endocrinology and oncology care can support demand over time.

Europe remains a major geographic cluster in the octreotide market, with Germany, France, and the United Kingdom serving as key contributors. The region has experienced generic competition in long-acting release products and maintains an established network of specialist centers. Novartis is expected to report continued pressure on Sandostatin long-acting release (LAR) from generic competition in its 2025 annual report. Europe also plays an important role in developing longer-interval products, with Debiopharm expected to initiate the Phase III OXTEND-03 trial across 75 sites in 21 countries in December 2025. South America and the Middle East and Africa offer opportunities to improve patient access as diagnostic capabilities and specialist care expand. Progress in these regions will depend on referral pathways, specialist availability, and reimbursement support.



List of Companies Covered in this Report:

  1. Amneal Pharmaceuticals
  2. Aurobindo Pharma
  3. Bachem Holding
  4. BCN Peptides, S.A.
  5. Cipla
  6. Dr. Reddy’s Laboratories
  7. Fresenius
  8. GLAND PHARMA
  9. Hikma Pharmaceuticals
  10. Lupin
  11. Novartis
  12. PolyPeptide Group AG
  13. Sagent Pharmaceuticals, Inc.
  14. Sun Pharmaceuticals Industries
  15. Teva Pharmaceutical Industries
  16. USV Private Limited
  17. Viatris
  18. Zydus Lifesciences Limited

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expanding Use in Neuroendocrine Tumors
4.2.2 Persistent Demand for Acromegaly Maintenance Therapy
4.2.3 Generic Long-Acting-Release Entry Expanding Treatment Access
4.2.4 Oral and Self-Administered Somatostatin-Pathway Innovation
4.2.5 Monthly Depot Supply-Chain Resilience as a Formulary Differentiator
4.2.6 Improved Conversion from Short-Acting to Depot Therapy
4.3 Market Restraints
4.3.1 Generic Price Erosion in Long-Acting-Release Products
4.3.2 Complex Depot Manufacturing and Bioequivalence Requirements
4.3.3 Limited Patient Pool for Rare Endocrine Disorders
4.3.4 Buy-and-Bill and Site-of-Care Reimbursement Friction
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
5.1 By Product Type
5.1.1 Branded Octreotide
5.1.2 Generic Octreotide
5.2 By Formulation
5.2.1 Immediate-Release Injection
5.2.2 Long-Acting-Release Injectable Suspension
5.2.3 Depot Microsphere Injection
5.2.4 Other Extended-Release Formulations
5.3 By Route of Administration
5.3.1 Subcutaneous
5.3.2 Intravenous
5.3.3 Intramuscular
5.3.4 Oral and Other Investigational Routes
5.4 By Indication
5.4.1 Acromegaly
5.4.2 Gastroenteropancreatic Neuroendocrine Tumors
5.4.3 Carcinoid Syndrome
5.4.4 Vasoactive Intestinal Peptide-Secreting Tumors
5.4.5 Secretory Diarrhea
5.4.6 Esophageal Variceal Bleeding
5.4.7 Other Clinical Indications
5.5 By End User
5.5.1 Hospitals
5.5.2 Specialty Clinics
5.5.3 Endocrinology Clinics
5.5.4 Oncology Centers
5.5.5 Ambulatory Care Centers
5.5.6 Others
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 India
5.6.3.3 Japan
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Amneal Pharmaceuticals, Inc.
6.3.2 Aurobindo Pharma Limited
6.3.3 Bachem Holding AG
6.3.4 BCN Peptides, S.A.
6.3.5 Cipla Limited
6.3.6 Dr. Reddy's Laboratories Limited
6.3.7 Fresenius Kabi AG
6.3.8 Gland Pharma Limited
6.3.9 Hikma Pharmaceuticals PLC
6.3.10 Lupin Limited
6.3.11 Novartis AG
6.3.12 PolyPeptide Group AG
6.3.13 Sagent Pharmaceuticals, Inc.
6.3.14 Sun Pharmaceutical Industries Limited
6.3.15 Teva Pharmaceutical Industries Ltd.
6.3.16 USV Private Limited
6.3.17 Viatris Inc.
6.3.18 Zydus Lifesciences Limited
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bachem Holding AG
  • BCN Peptides, S.A.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Novartis AG
  • PolyPeptide Group AG
  • Sagent Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • USV Private Limited
  • Viatris Inc.
  • Zydus Lifesciences Limited